
Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).

Your AI-Trained Oncology Knowledge Connection!


Published: June 18th 2014 | Updated: